AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00114777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept More Intensive Regimen (MI)
Description: solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
Study NCT03447145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3203
Description: dose escalation, 2/4/6/10/14/18mg/m2
Study NCT02122952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVXS-101
Description: Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
Study NCT01284764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mosapride
Description: Mosapride 10mg, one dosage, once evening of the day before the endoscopy
Study NCT00629239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4818
Description: Dry Powder, inhalation, b.i.d., 4 weeks
Study NCT00629239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00793065 — intervention group
Intervention type: OTHER
Intervention: Electronic health record (EHR)
Description: Computer-based system that allows physicians to access and manage patient records electronically.
Study NCT00793065 — intervention group
Intervention type: OTHER
Intervention: Medical Home redesign
Description: Implementation of NCQA Level III Medical Home
Study NCT02663505 — intervention group
Intervention type: PROCEDURE
Intervention: Patients receiving the surgery planned for them
Description: For each patient the following potential influence (risk) factors are documented:~sex, urgency of the operation, BMI, age, ASA classification, preconditions, physical fitness, Hb value.~In phase 2 only selected influence factors will be recorded.~No intervention will be performed apart from the surgery planned for each patient.
Study NCT02162563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX/ FOLFIRI with bevacizumab
Description: FOLFIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks
Study NCT02162563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI with bevacizumab
Description: FOLFOXIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 165 mg/m2 i.v. in 60 minutes, followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours, every 2 weeks
Study NCT02162563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX/ FOLFIRI with panitumumab
Description: FOLFIRI + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, and bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks
Study NCT03044561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: 25 mg orally, 4 times per day for 21 days
Study NCT03044561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: orally, 4 times per day for 21 days
Study NCT02049879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids injection
Description: A solution of triamcinolone 40 mg (Kenalog) mixed with 3 cc of 2% xylocaine without epinephrine.
Study NCT02112175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT01471327 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-240563
Description: 10mg, 75mg, 250mg and 750mg IV, single dose on Day 1
Study NCT01471327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline IV, single dose at Day 1
Study NCT02128490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat IR
Description: Febuxostat IR over-encapsulated tablets
Study NCT02128490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat XR
Description: Febuxostat over-encapsulated capsules
Study NCT02128490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Febuxostat placebo
Description: Febuxostat IR and XR placebo-matching capsules
Study NCT02128490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine tablets
Study NCT02128490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine tablets
Study NCT02128490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine
Description: Colchicine tablets
Study NCT02128490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen tablets
Study NCT02128490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen tablets
Study NCT02128490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen
Description: Naproxen tablets
Study NCT02128490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole capsules
Study NCT02128490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole capsules
Study NCT02128490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole capsules
Study NCT04240743 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cephalomedullary nail
Description: For patients in the cephalomedullary nail group, an incision was made in the gluteal area from the tip of the greater trochanter in proximal orientation. A guidewire was placed into the medullary canal from slightly medial to the exact tip of the greater trochanter. The entry point of the greater trochanter and proximal medullary canal were reamed. The cephalomedullary nail was then inserted and fixed to the femoral head with a double screw. The cephalomedullary nail was then locked distally using a guide arm. These cephalomedullary nails were not locked proximally to maintain dynamization and to allow compression across the basicervical fracture line.
Study NCT04240743 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sliding hip screw
Description: For patients in the sliding hip screw group, a lateral incision was made over the lateral proximal aspect of the femur. Under fluoroscopic guidance, the lag screw was placed centrally in the femoral head over the guidewire. A side plate with three holes was then attached to the hip screw.
Study NCT03361670 — intervention group
Intervention type: OTHER
Intervention: Observational Study
Study NCT01753492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ologen
Study NCT00224016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: 1.3, 2.6, 3.9 mg/day transdermal
Study NCT00224016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: 5 to 15 mg/day immediate release or extended release tablets, or syrup
Study NCT04684030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system(CGMS)
Description: Patients will randomized 1:1 to either continuous glucose monitoring system(CGMS) or conventional self-monitoring of blood glucose (SMBG) group. After the randomization, patients in CGMS group will given education on how to use the device and check the result using the smart phone. The data collected from the sensors were computed to generate the respective ambulatory glucose profiles so as to determine the total numbers of scans conducted during the study period.
Study NCT04684030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring of blood glucose (conventional fingerpricking method)
Description: Patients will randomized 1:1 to either continuous glucose monitoring system(CGMS) or conventional self-monitoring of blood glucose (SMBG) group. After the randomization, patients in SMBG group will check their blood glucose by finger pricking method and record the data in a notebook to share the data in their outpatient clinic visit.
Study NCT02895490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: communication skills training
Description: Receive a DVD containing educational information and communication skills
Study NCT02895490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Receive information about the LINC group
Study NCT02895490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02895490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02895490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02895490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT03809637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed, cisplatin
Description: Pemetrexed 500mg/m2, Intravenous, Q 3weeks. Cisplatin 75mg/m2, Intravenous, Q 3weeks. Combination administration : up to 6cycles After 6 cycle, pemetrexed alone is administered.
Study NCT04324463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: oral medication
Study NCT04324463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-Beta
Description: subcutaneous injection
Study NCT04324463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: oral medication
Study NCT04324463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: oral medication
Study NCT01554982 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ferric citrate
Description: Dose based on monthly serum phosphorus levels with goal of 3.5-5.5 mg/dL for all patients.
Study NCT04118985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation and health behavior change intervention
Description: Cognitive rehabilitation and health behavior change intervention in a group-based program intervention compared to self-implementation of techniques without these interventions
Study NCT04118985 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-implementation
Description: Self-implementation of cognitive rehabilitation and health behavior change recommendations
Study NCT00641160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Dose Level #1 PO for at least 7 days
Study NCT00641160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Dose Level #2 PO for at least 7 days
Study NCT00641160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Dose Level #3 PO for at least 7 days
Study NCT02377830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-bed cycle ergometer (Restorative Therapies RT300 Supine)
Study NCT03129763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 100mmHg capsule pressure expansion
Description: With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 100mmHg.
Study NCT01499186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Vibration
Description: The subjects of the vibration group will be subjected to local vibration training by the use of custom-made cylindrical vibrators which will be placed on the hip and thigh. The subjects will apply the vibrations by themselves and they will learn how to follow the pre-programmed training program. Training sessions take place 5 times a week, during one year. The physiotherapist and the research assistant will attend the training session 1x/week. Training parameters will vary during the year to create a variable stimulus (frequency 40-80Hz and G-force 0.5-5g). The intervention group will perform all measurements.
Study NCT03855371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20mg/m2/d, intravenously, d1-d5, q4w
Study NCT03855371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: 0.16mg/kg/d, intravenously, d1-d5, q4w(maximum dose: 10mg/d)
Study NCT00032487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs Arm 1 Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs, add one injection of insulin Arm 2
Study NCT02377830 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physiotherapy
Description: activities to assist with optimizing airway clearance and respiratory function, and, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out of bed mobility, and ambulation
Study NCT00033735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 5-fluorouracil will be administered via central venous catheter or PICC beginning at 250mg/m2/ day as continous infusion for a 28 day period.
Study NCT00033735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irofulven
Description: Irofulven will be given at 0.55 mg/kg per infusion on Day 1 and and Day 15 every 28 days as a 30 minute iv infusion.
Study NCT01364415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Study NCT04215094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: postoperative fever, serum procalcitonin, C-reactive protein and white blood cell coun
Description: All patients in Intracranial Infection group were cured with antibiotic treatment
Study NCT00718133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spirometry (Pony spirometer)
Description: Spirometry at rest
Study NCT02240134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Intervention (Tx1)
Description: The intervention will be a combination of a strong education campaign coupled with the distribution of inexpensive tools to the homes that will enable the residents to burn wood more efficiently.
Study NCT02240134 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Filtration Unit Treatment (Tx2)
Description: A 20 x 18 Filtrete air filtration unit (Ultra Clean Air Purifiers, 3M, St. Paul, MN) will be placed in the same room as the wood stove. These units are rated by their ability to provide an equivalent amount of contaminant free air into the space, and have a smoke Clean Air Delivery Rate of 112. The electrostatically charged filters in these units are approximately 85% efficient at removing 0.2 micron particles (cigarette smoke size particles) and over 95% efficient at removing 3 micron particles. The unit will be operated on the high setting throughout the duration of the six-month assessment winter periods. Filters will be changed out by the Community Coordinator approximately once per month in an effort to maximize collection efficiency.
Study NCT02240134 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo Intervention (Tx3)
Description: Similar to Tx1, a 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter.
Study NCT00391599 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: enema
Study NCT00391599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: enema
Study NCT01568216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 747
Description: Three dose levels once-daily oral administration
Study NCT01568216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral administration
Study NCT04207398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunts
Description: Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver. A small metal device called a stent is placed to keep the connection open and allow it to bring blood draining from the bowel back to the heart. TIPS may successfully reduce internal bleeding in the stomach and esophagus in patients with cirrhosis and may also reduce the accumulation of fluid in the abdomen (ascites).
Study NCT04207398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nonselective β-blocker (NSBB)+ endoscopic band ligation (EBL)
Description: Combination therapy of nonselective β-blocker (NSBB) and endoscopic variceal ligation (EBL) will be used for participants in this group. NSBB, which will be titrated to the maximum tolerated dose aiming to decrease the heart rate by 25%, with a lower limit of 50 beats per minute, was started at day 5 after the index bleeding, unless a contraindication was present (severe arrhythmia, severe obstructive chronic obstructive pulmonary disease, or known intolerance). Endoscopic variceal ligation sessions started 2 weeks after the index bleeding and were performed every 2-4 weeks thereafter until eradication of varices, followed by endoscopic surveillance and retreatment, if indicated, every 6-12 months.
Study NCT03702608 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: EluNIR Ridaforolimus Eluting Coronary Stent System
Description: The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:~* Stent - a mounted Cobalt Chromium (CoCr) alloy based stent - 38 mm length and 2.75mm, 3.0 mm, 3.5mm, 4.0mm diameter~* Delivery System - Rapid Exchange (RX) Coronary System~* Polymer matrix coating - (PBMA) and CarboSil®~* Ridaforolimus drug
Study NCT05468879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glimepiride is a sulfonylurea, indicated as an adjunct to proper dietary management, exercise and weight reduction to lower the blood glucose in patients with type 2 diabetes whose hyperglycemia cannot be controlled by diet and exercise alone.
Study NCT05468879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amaryl®
Description: Amaryl®
Study NCT03552718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YE-NEO-001
Description: Personalized recombinant yeast-based vaccine engineered to express multiple neoantigen epitopes (neoepitopes) based on an individual subject's tumor molecular profile.
Study NCT01938859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Lithium plasma concentration was between 0.6-1.2 mmol/L, dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
Study NCT01938859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: Lithium plasma concentration was between 0.6-1.2 mmol/L, dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
Study NCT01938859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Quetiapine adjunctively to lithium therapy, target 400 mg/d with a minimum dose of 200 mg/d. Dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
Study NCT01938859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shuganjieyu capsule
Description: Shuganjieyu capsule adjunctively to lithium therapy, target dose 1440 mg/d.
Study NCT02786641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 65mg/m2 in induction chemotherapy
Study NCT02786641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 1
Description: Cisplatin 75mg/m2 in induction chemotherapy
Study NCT02786641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Xeloda 2000mg/m2 D1-14 in induction chemotherapy
Study NCT02786641 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: IMRT for all patients
Study NCT02786641 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT for all patients
Study NCT02786641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin 2
Description: Cisplatin 100mg/m2 in concurrent chemotherapy
Study NCT02786641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 2
Description: Cisplatin 100mg/m2 in concurrent chemotherapy
Study NCT04972383 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: In the Platelet Rich Plasma group, 4mL Platelet Rich Plasma was given.